Search Results
Keyword：Boron Neutron Capture Therapy
Fujita Health University in Japan Advances Research on Expanding BNCT Indications for Deep-Seated Cancers, to Conduct 18F-FBPA PET Exploratory Evaluation
On August 10, Stella Pharma Corporation of Japan announced that it is collaborating with Fujita Health University and other institutions to advance research and development aimed at expanding Boron Neutron Capture Therapy (BNCT) to deep-seated cancers. As part of this project, Stella Pharma will participate in an exploratory study on 18F-FBPA uptake capacity in deep-seated cancers conducted by Fujita Health University. The study will use 18F-FBPA PET to evaluate the tumor accumulation of boron drugs used in BNCT in deep-seated cancers, and based on the findings, explore the possibility of expanding BNCT indications in the future. The study plans to collect data from 50 cases, including pancreatic cancer, hepatocellular carcinoma, and biliary tract cancer, to accumulate foundational evidence needed for the development of BNCT for deep-seated cancers. BNC...
2026-08-11
Russia's Vector Research Center Proposes Quantum Dots for Boron Delivery in Neutron Capture Therapy
Russia's Vector Research Center has proposed using quantum dots as targeted boron delivery systems in boron neutron capture therapy (BNCT) to explore more precise approaches to tumor treatment. Yuri Tumanov, the center's chief researcher, presented this research progress at a conference on engineering biology and biopharmaceuticals. Boron neutron capture therapy is a cancer treatment method that combines boron-containing drugs with neutron irradiation. The basic concept involves first allowing boron-containing drugs to accumulate in tumor cells, then subjecting the patient to neutron irradiation, which triggers a nuclear reaction that releases energy concentrated within boron-containing cancer cells, thereby destroying tumor cells. How to construct boron delivery systems that are low-toxicity, highly efficient, and capable of participating in targeted tumor destruction remains one of the key challenges in this field...
2026-08-01